Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer
Alica K. Beutel, Sabrina E. Calderon, Ethan Nghiem, Kevin Christian Montecillo Gulay, Leonor Patricia Schubert Santana, Eleni Zimmer, Rima Singh, Cecily Anaraki, Natalie Yousefian, Chantal Allgöwer, Gregory Tong, Cameron Geller, Alina Chao, Dennis Juarez, Thomas Theodor Werner Seufferlein, , Christopher J. Halbrook
This study identifies mevalonate biosynthesis as a therapeutic target and biomarker for gemcitabine-resistant pancreatic cancer.
bioRxiv · Sep 19, 2025 · PreprintCancer Biology